Treatment for Pulmonary Arterial Hypertension Cleared PDF Print E-mail
Thursday, 17 September 2009 14:50
taken from http://www.flickr.com/photos/dhedwards/383835919/Renal & Urology News has recently reported in its September Issue that the FDA has cleared Tyvaso (treprostinil) Inhalation Solution for the treatment of pulmonary arterial hypertension (PAH). Developed by United Therapeutics Corp., of Silver Spring, Md., treprostinil is indicated to increase walk distance in patients with New York Heart Association Class III symptoms associated with WHO Group I PAH, which includes multiple etiologies such as idiopathic and familial PAH as well as PAH associated with Scleroderma and congenital heart disease.

In the TRIUMPH-1 randomized, double-blind, 12-week, placebo-controlled clinical trial, patients taking treprostinil in four daily inhalation sessions achieved a 20-meter improvement in six-minute walk distance compared with placebo recipients. The safety and effectiveness in patients with underlying lung disease has not been established. The most common side effects seen with treprostinil were cough, headache, nausea, dizziness, flushing, throat irritation, pharyngolaryngeal pain, and diarrhea.
 
More articles :

» Eating Well: Nutritional Needs in Scleroderma

The purpose of this article is to identify nutritional needs in and provide practical food advice, with the two goals of minimizing nutrition-related side effects and to improve your overall nutritional health. Since Scleroderma can be manifested...

» Raynaud's Syndrome

John W. Hallett, Jr., MDJanuary 2008Raynaud's syndrome is vasospasm of parts of the hand in response to cold or emotional stress, causing reversible discomfort and color changes (pallor, cyanosis, erythema, or a combination) in one or more digits....

» Blocking TGFβ via Inhibition of the αvβ6 Integrin: A Possible Therapy for Systemic Sclerosis Interstitial Lung Disease

Tamiko R. Katsumoto, Shelia M. Violette, and Dean SheppardReceived 27 May 2011; Accepted 15 August 2011Interstitial lung disease (ILD) is a commonly encountered complication of systemic sclerosis (SSc) and accounts for a significant proportion of...

» Virus Proves Protective Against Lupus In Mice

A viral infection may help combat lupus. The mouse version of a virus thought to be a prime suspect in the disease, the Epstein-Barr virus, actually prevents certain features of the autoimmune disease, a study in mice shows.“It might be that this...

» Management

Our Management Team or Executive Committee is presently responsible for the daily operations of the Scleroderma Care Foundation, realizing its vision, and similarly ensuring its growth and future success. Adelwyn Holder, Co-Founder &...

» Targeted Therapy for Systemic Sclerosis: How Close are We?

Manuel Ramos-Casals; Vicent Fonollosa-Pla; Pilar Brito-Zerón; Antoni Sisó-AlmirallPosted: 09/14/2010; Nat Rev Rheumatol. 2010;6(5):269-278. © 2010 Nature Publishing GroupDespite recent etiopathogenetic advances, systemic sclerosis continues to be...